CRGX (Cargo Therapeutics) Tax Provision : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics Tax Provision?

Cargo Therapeutics's tax provision for the three months ended in Sep. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Cargo Therapeutics Tax Provision Historical Data

The historical data trend for Cargo Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics Tax Provision Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Tax Provision

Cargo Therapeutics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial						-	-	-	-	-

Cargo Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cargo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.